Literature DB >> 34761362

Ayahuasca for the Treatment of Depression.

Fernanda Palhano-Fontes1,2, Bruno Lobão Soares3,4, Nicole Leite Galvão-Coelho3,5, Emerson Arcoverde2, Draulio B Araujo6,7.   

Abstract

Ayahuasca, the vine of the souls in Quechua, is a psychedelic brew with a few formulations that most often include the bark of a liana in the Malpighiaceae family (Banisteriopsis caapi), with leaves from a shrub in the coffee family Rubiaceae (Psychotria viridis). Mixed with water and boiled for hours or days, it produces a brownish-colored liquid with a strong and characteristic taste. Ayahuasca contains the psychedelic tryptamine N,N-Dimethyltryptamine (DMT), and Monoamine Oxidase Inhibitors (MAOi), and in the past few years, it has been tested. In recent years its antidepressant properties have been put to the test. Evidence from open and randomized placebo-controlled clinical trials has shown encouraging results, indicating significant and rapid antidepressant effects, starting as early as 1 day after the ayahuasca intervention. In addition, we have explored the nature of these effects using multivariate measures. In this article, we will review the history, pharmacology, clinical trials, and clinical and behavioral markers associated with the antidepressant effects of ayahuasca.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Ayahuasca; DMT; MAOi; Monoamine Oxidase Inhibitors; N,N-Dimethyltryptamine; Treatment-resistant depression

Mesh:

Substances:

Year:  2022        PMID: 34761362     DOI: 10.1007/7854_2021_277

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  38 in total

Review 1.  Health status of ayahuasca users.

Authors:  Paulo Cesar Ribeiro Barbosa; Suely Mizumoto; Michael P Bogenschutz; Rick J Strassman
Journal:  Drug Test Anal       Date:  2012-07-04       Impact factor: 3.345

2.  Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil.

Authors:  Paulo Cesar Ribeiro Barbosa; Joel Sales Giglio; Paulo Dalgalarrondo
Journal:  J Psychoactive Drugs       Date:  2005-06

3.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

4.  A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naïve subjects.

Authors:  Paulo Cesar Ribeiro Barbosa; Irene Maurício Cazorla; Joel Sales Giglio; Rick Strassman
Journal:  J Psychoactive Drugs       Date:  2009-09

5.  Pharmacokinetics of Hoasca alkaloids in healthy humans.

Authors:  J C Callaway; D J McKenna; C S Grob; G S Brito; L P Raymon; R E Poland; E N Andrade; E O Andrade; D C Mash
Journal:  J Ethnopharmacol       Date:  1999-06       Impact factor: 4.360

Review 6.  New hypothesis and treatment targets of depression: an integrated view of key findings.

Authors:  Shangli Cai; Shucai Huang; Wei Hao
Journal:  Neurosci Bull       Date:  2015-01-09       Impact factor: 5.203

Review 7.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

8.  Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.

Authors:  Robin L Carhart-Harris; Leor Roseman; Mark Bolstridge; Lysia Demetriou; J Nienke Pannekoek; Matthew B Wall; Mark Tanner; Mendel Kaelen; John McGonigle; Kevin Murphy; Robert Leech; H Valerie Curran; David J Nutt
Journal:  Sci Rep       Date:  2017-10-13       Impact factor: 4.379

9.  A non-hallucinogenic psychedelic analogue with therapeutic potential.

Authors:  Lindsay P Cameron; Robert J Tombari; Ju Lu; Alexander J Pell; Zefan Q Hurley; Yann Ehinger; Maxemiliano V Vargas; Matthew N McCarroll; Jack C Taylor; Douglas Myers-Turnbull; Taohui Liu; Bianca Yaghoobi; Lauren J Laskowski; Emilie I Anderson; Guoliang Zhang; Jayashri Viswanathan; Brandon M Brown; Michelle Tjia; Lee E Dunlap; Zachary T Rabow; Oliver Fiehn; Heike Wulff; John D McCorvy; Pamela J Lein; David Kokel; Dorit Ron; Jamie Peters; Yi Zuo; David E Olson
Journal:  Nature       Date:  2020-12-09       Impact factor: 49.962

10.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.